Citius Pharmaceuticals, Inc.CTXR
Oncology6 cited findings · profile updated 2026-08-20
0.64 USDnot live — refreshed daily
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (CTXR) is an oncology research site. The company's portfolio includes LYMPHIR, which has been studied in combination with pembrolizumab, demonstrating an overall response rate (ORR) of 24% and a clinical benefit rate of 48%. In this setting, the median progression-free survival was 20.5 months. LYMPHIR has also been investigated when administered prior to CAR-T therapy, where it achieved an objective response rate (ORR) of 86%. This included a complete response (CR) rate of 57% and a partial response (PR) rate of 29% when LYMPHIR was administered prior to CAR-T therapy.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Overall response rate (ORR) | 24% (LYMPHIR in combination with pembrolizumab) | Citius Pharmaceuticals, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Clinical benefit rate | 48% (LYMPHIR in combination with pembrolizumab) | Citius Pharmaceuticals, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Median progression-free survival | 20.5 months (LYMPHIR in combination with pembrolizumab) | Citius Pharmaceuticals, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Objective response rate (ORR) | 86% (LYMPHIR administered prior to CAR-T therapy) | Citius Pharmaceuticals, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Complete response (CR) | 57% (LYMPHIR administered prior to CAR-T therapy) | Citius Pharmaceuticals, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Partial response (PR) | 29% (LYMPHIR administered prior to CAR-T therapy) | Citius Pharmaceuticals, Inc. — SEC 8-K (2026-08-14), p.p.2 |
Key projects
- LYMPHIR (in combination with pembrolizumab)
LYMPHIR in combination with pembrolizumab demonstrated an overall response rate (ORR) of 24%.
- LYMPHIR (administered prior to CAR-T therapy)
LYMPHIR administered prior to CAR-T therapy achieved an objective response rate (ORR) of 86%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →